Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating resectable stage II or III esophageal squamous cell carcinoma (ESCC). However, 5-fluorouracil plus cisplatin does not benefit cohorts with clinical stage III ESCC, suggesting the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Mitsuro, Shimizu, Dai, Miyata, Kazushi, Maeda, Osamu, Tanaka, Chie, Inokawa, Yoshikuni, Hattori, Norofumi, Hayashi, Masamichi, Ando, Masahiko, Kuwatsuka, Yachiyo, Murotani, Kenta, Nakayama, Goro, Koike, Masahiko, Ando, Yuichi, Ebata, Tomoki, Kodera, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601964/
https://www.ncbi.nlm.nih.gov/pubmed/34820548
http://dx.doi.org/10.1016/j.conctc.2021.100853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601964/
https://www.ncbi.nlm.nih.gov/pubmed/34820548
http://dx.doi.org/10.1016/j.conctc.2021.100853

Ejemplares similares